journal article·2022-09

Photoactivatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy

Mei Lu, Haonan Xing, Wanxuan Shao, Tian Zhang, Mengjie Zhang, Yongchao Wang, Fangzhou Li, Yuhua Weng, Aiping Zheng, Yuanyu Huang, Xing‐Jie Liang

Advanced Materials· Volume 34· Issue 35
Publisher page

Abstract

Abstract Immunotherapy has delivered impressive outcomes in combating tumor malignancies. However, insufficient immune infiltration and poor immunogenicity within the tumor microenvironment (TME) greatly compromise patient response rates. Here, a photoactivatable silencing extracellular vesicle (PASEV) is developed for sensitized cancer immunotherapy. p21‐Activated kinase 4 (PAK4) is a newly identified tumor‐cell‐intrinsic “guard” associated with immune exclusion. Small interfering RNA against PAK4 (siPAK4) is designed and assembled with a photoactivatable reactive‐oxygen‐species (ROS)‐sensitive polymer to form the nanocomplex core, which is further camouflaged by extracellular vesicles from M1 macrophages. The PASEV not only serves as a vehicle for packaging, tumor accumulation, and ROS‐responsive release of siPAK4 for potent PAK4 silencing, but also primes the TME through immunogenic phototherapy, thereby simultaneously boosting intratumoral infiltration and immune activation. The combined immunotherapy elicits robust anticancer immunity, thus showing great promise for fighting cancers. This work opens a new avenue to simultaneously boost intratumoral infiltration and immune activation for sensitized cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Advanced Research Institute of Multidisciplinary Science School of Life Science School of Medical Technology (Institute of Engineering Medicine) Key Laboratory of Molecular Medicine and Biotherapy Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering Beijing Institute of Technology Beijing 100081 China

Chinese Academy of Sciences (CAS) Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing 100190 China

State Key Laboratory of Toxicology and Medical Countermeasures Beijing Institute of Pharmacology and Toxicology Beijing 100850 China

Funding

National Key Research and Development Program of China · Natural Science Foundation of Beijing Municipality · National Natural Science Foundation of China · China Postdoctoral Science Foundation

References (46)

Show source-provided references
1. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
2. 10.1038/s41586-019-1593-510.1038/s41586-019-1593-5 ↗
3. 10.1038/s41573-022-00493-510.1038/s41573-022-00493-5 ↗
4. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
5. 10.1016/j.cell.2018.09.00610.1016/j.cell.2018.09.006 ↗
6. 10.1038/s41571-019-0308-z10.1038/s41571-019-0308-z ↗
7. 10.1158/2159-8290.CD-17-132710.1158/2159-8290.CD-17-1327 ↗
8. 10.1038/nature1440410.1038/nature14404 ↗
9. 10.1038/s43018-019-0012-z10.1038/s43018-019-0012-z ↗
10. 10.1038/s43018-019-0003-010.1038/s43018-019-0003-0 ↗
11. 10.1038/s41573-019-0017-410.1038/s41573-019-0017-4 ↗
12. 10.1016/j.ijpharm.2017.01.05610.1016/j.ijpharm.2017.01.056 ↗
13. 10.1038/s41565-020-00782-310.1038/s41565-020-00782-3 ↗
14. 10.1002/adfm.20180468810.1002/adfm.201804688 ↗
15. 10.1038/nrc189410.1038/nrc1894 ↗
16. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
17. 10.7150/thno.3758610.7150/thno.37586 ↗
18. 10.1021/acsnano.9b0418110.1021/acsnano.9b04181 ↗
19. 10.1016/j.biotechadv.2019.04.01210.1016/j.biotechadv.2019.04.012 ↗
20. 10.1002/EXP.2021000810.1002/EXP.20210008 ↗
21. 10.1038/nature2234110.1038/nature22341 ↗
22. 10.1016/j.ajps.2017.07.00810.1016/j.ajps.2017.07.008 ↗
23. 10.1016/j.addr.2020.04.00410.1016/j.addr.2020.04.004 ↗
24. 10.1021/acsnano.8b0244610.1021/acsnano.8b02446 ↗
25. 10.1016/j.ejpb.2017.07.01010.1016/j.ejpb.2017.07.010 ↗
26. 10.3402/jev.v5.3102710.3402/jev.v5.31027 ↗
27. 10.1016/j.jconrel.2017.11.00210.1016/j.jconrel.2017.11.002 ↗
28. 10.1002/EXP.2021000310.1002/EXP.20210003 ↗
29. 10.1016/j.actbio.2019.07.00610.1016/j.actbio.2019.07.006 ↗
30. 10.1016/j.biomaterials.2020.11992510.1016/j.biomaterials.2020.119925 ↗
31. 10.1021/jacs.8b0358410.1021/jacs.8b03584 ↗
32. 10.1038/s41467-019-11718-410.1038/s41467-019-11718-4 ↗
33. 10.1021/ar200227n10.1021/ar200227n ↗
34. 10.1016/j.jconrel.2010.06.00810.1016/j.jconrel.2010.06.008 ↗
35. 10.1038/nrc364510.1038/nrc3645 ↗
36. 10.1038/nrc189210.1038/nrc1892 ↗
37. 10.1158/1535-7163.MCT-16-019710.1158/1535-7163.MCT-16-0197 ↗
38. 10.1002/anie.20180488210.1002/anie.201804882 ↗
39. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
40. 10.1038/nature0312110.1038/nature03121 ↗
41. 10.1038/nbt.376510.1038/nbt.3765 ↗
42. 10.1016/j.actbio.2018.12.04110.1016/j.actbio.2018.12.041 ↗
43. 10.1073/pnas.190198711610.1073/pnas.1901987116 ↗
44. 10.1002/eji.20104109310.1002/eji.201041093 ↗
45. 10.1158/0008-5472.CAN-15-173710.1158/0008-5472.CAN-15-1737 ↗
46. 10.1038/3507412210.1038/35074122 ↗